Answers are grounded in this paper and cite their sources.
T cells against tumor-associated antigens. STING agonists are therefore being developed as a novel cancer therapeutic, and a greater understanding of STING pathway regulation is leading to a broadened list of candidate immune regulatory targets. Early phase clinical trials of intratumoral STING agonists are already showing promise, alone and in combination with checkpoint blockade. Further advancement will derive from a deeper understanding of STING pathway biology as well as mechanisms of response vs resistance in individual cancer patients.
No takes yet. Share an insight, caveat, or question.
Flood et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: